Getting a drug that might save lives through the development process and on to the market is a notoriously sluggish business, but a new software business in New York City is hoping to speed things up. Solstice, an AI-native marketing platform for the pharmaceutical and life sciences industries, announced that it has raised $21 million in Series A financing.
The company raised a seed round, which was led by Transformation Capital, a leading growth equity venture firm focused on digital health. The round included participation by the company’s existing seed investors, Twelve Below and Virtue Ventures, as well as multiple strategic angel investors. The new round increased Solstice’s funding to roughly $25 million.
The capital will be used to fund the company’s go-to-market expansion, accelerate product engineering, and substantially grow the company’s own product and customer success teams.
The Multi-Billion Dollar Bottleneck
The global market for biopharmaceutical companies is forecasted to go above $100 billion in drug sales this year alone. The huge budget, however, has little impact; launching and promoting a therapy is still restrained by old workflows.
The most common offender is the Medical, Legal and Regulatory (MLR) review. Since the advertising of medicines is heavily controlled for reasons of patient safety, each piece of material – whether it is a complicated clinical take, an out-of-pamphlet aimed at health professionals or an introductory electronic message aimed at the wider world – has to be reviewed thoroughly for balance, medical content and legal validity.
Source: Solstice Health
The average time it takes to move a single marketing asset through prescribed internal MLR processes is three months and at least three cycles. With the time period for drug patents becoming more rigid, the consequence of an MLR review taking longer than expected is a delay in access to the drug for patients and a regression of profits. “Few business challenges are as high-stakes and time-sensitive as commercializing a new drug,” said Aris Saxena, co-founder and CEO of Solstice. “We built Solstice to ensure that we can substantiate all of a product’s marketing claims using clinical data before they even reach the MLR desk. While it used to take us three to five review cycles, we now merge that down to one or two, compressing months into just 10 days.”
More News: Capchase Raises $200M+ to Expand Financing Platform
AI Built for Strict Compliance
Set up in 2023 by Li Yiwen and Aris Saxena, Solstice sidesteps the trap of being a one-size-fits-all generative AI littered with ‘hallucinations’ that aren’t appropriate in heavily regulated industries. Instead, Solstice is a kind of AI-native appliance that integrates its three most basic pillars of commercialization:
- Clinical Grounding: The system automatically queries drafted medical claims against dense clinical literature and trial data, fact-checking for non-compliant language or early regulatory risk.
- Unified Content Creation: It can help marketing teams create on-brand, very precise educational content created specifically for physicians or consumers.
- Performance Metrics: The platform tracks which compliant content is successfully driving physician adoption and patient engagement.
Through automating the otherwise time-consuming claim mapping when an ad marketer must manually match each sentence with a particular page of a clinical trial report, Solstice, for the first several corporate users, has eliminated up to 84% of operational inefficiencies.
The Shift to “Speed-to-Market” Advantage
With the pharmaceutical playing field increasingly crowded with niche biologics and rare, disease-specific companies, commercial agility has become a differentiator. For investors, Solstice’s specialist has become less a luxury and more a necessity.
With its new $21M balance sheet, Solstice is the one company that can really turn from a promising software vendor to the de facto OS for biopharma commercialization. By allowing brands to cut their regulatory turnaround times to less than 48 hours in some cases, Solstice has quietly defined the way forward for the delivery of modern medicine to the market.
